Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2023-10-31 M&A Activity
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: NanoRepro zeichnet Aktien der Deutsche Kosmetikwerke AG zum Gesamtbetrag von EUR 2,7 Mio. und erhalt Kaufoption fur weitere Aktien
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated October 31, 2023, explicitly stating it is an 'Insiderinformation gem. Artikel 17 MAR' (Insider Information according to Article 17 MAR). It details a specific corporate action: NanoRepro AG subscribing to shares of Deutsche Kosmetikwerke AG for EUR 2.7 million and receiving a purchase option. This type of mandatory disclosure regarding significant corporate events, especially those related to financing, investments, or capital structure changes, falls under specific regulatory categories. Since it involves a significant investment/subscription (a form of financing/capital activity) and is an immediate regulatory disclosure (Ad-hoc/MAR), it aligns best with 'Capital/Financing Update' (CAP). While it is a regulatory filing, CAP is more specific than the general 'RNS' fallback. The document is short and is the primary announcement, not an announcement *of* another report.
2023-10-31 German
NanoRepro AG: NanoRepro plant den Erwerb einer strategischen Beteiligung von 37,5 % an der terraplasma medical GmbH
M&A Activity Classification · 95% confidence The document is an 'Ad-hoc' announcement dated October 31, 2023, explicitly stating it is an 'Insiderinformation gem. Artikel 17 MAR' (Insider Information according to Article 17 MAR). The content details NanoRepro AG's plan to acquire a 37.5% stake in terraplasma medical GmbH. This type of announcement, concerning material non-public information that must be disclosed immediately under EU market abuse regulation (MAR), is a mandatory regulatory disclosure. Since it is not a full annual report (10-K), an earnings release (ER), or a specific shareholder vote result (DVA), and it concerns a significant corporate transaction (M&A activity), the most fitting category is 'Regulatory Filings' (RNS) as a general mandatory disclosure, or potentially 'TAR' (M&A Activity). However, given the structure as an immediate MAR disclosure (Ad-hoc) and the general nature of mandatory regulatory news dissemination via EQS, RNS serves as a strong general classification for such immediate regulatory news that isn't explicitly covered by other specific report types. Since the core event is a potential acquisition/stake purchase, TAR (M&A Activity) is also highly relevant. Given the explicit mention of 'Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014', this is a primary regulatory disclosure. I will classify it as TAR because the substance is a transaction/takeover proposal, which aligns better than the general RNS fallback, even though it is disseminated via the regulatory news service.
2023-10-31 German
Halbjahresabschluss 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresabschluss' (Half-Year Financial Report) for NanoRepro AG for the period ending 30.06.2023. It contains a management report (Zwischenlagebericht) and financial statements (Bilanz, Gewinn- und Verlustrechnung). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H2 2023
2023-10-31 German
NanoRepro AG: Veroffentlichung von Kapitalmarktinformationen
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement dated October 30, 2023, detailing the acquisition of own shares ('Erwerb eigener Aktien: 24. Zwischenmeldung') under a previously announced share buyback program, referencing EU regulations (Regulation (EU) No 596/2014). This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The document is a regulatory disclosure about share repurchase activity, making 'POS' the most appropriate classification.
2023-10-30 German
NanoRepro AG: Veroffentlichung von Kapitalmarktinformationen
Transaction in Own Shares Classification · 100% confidence The document is a short corporate news release dated October 23, 2023, titled "NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen" (Publication of Capital Market Information). The key content revolves around the "Erwerb eigener Aktien: 23. Zwischenmeldung" (Acquisition of own shares: 23rd interim report) under an ongoing share buyback program, detailing the number of shares repurchased between October 16 and October 20, 2023. This directly relates to the company buying back its own stock. The filing type 'Transaction in Own Shares' (POS) is the most specific match for reporting share repurchases. Although it is an announcement, the core subject matter is the transaction itself, not just the announcement of a report (which would be RPA/RNS). Given the specific nature of the content (share repurchase details), POS is preferred over the general RPA or RNS.
2023-10-23 German
NanoRepro AG: Veroffentlichung von Kapitalmarktinformationen
Transaction in Own Shares Classification · 100% confidence The document is titled "NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen" (Publication of Capital Market Information) and specifically details the "Erwerb eigener Aktien: 22. Zwischenmeldung" (Acquisition of own shares: 22nd Interim Report). It provides daily transaction details (date, number of shares bought, volume-weighted average price) related to a share buyback program, referencing EU regulations (Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/1052). This content directly relates to the company purchasing its own stock. The classification 'Transaction in Own Shares' (POS) is the most appropriate fit for reporting share repurchases.
2023-10-16 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.